Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash from Operations: 2018-2019

Historic Cash from Operations for DiaMedica Therapeutics (DMAC) over the last 2 years, with Dec 2019 value amounting to -$1.9 million.

  • DiaMedica Therapeutics' Cash from Operations rose 1.84% to -$1.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$9.1 million, marking a year-over-year decrease of 59.80%. This contributed to the annual value of -$22.1 million for FY2024, which is 18.01% down from last year.
  • According to the latest figures from Q4 2019, DiaMedica Therapeutics' Cash from Operations is -$1.9 million, which was down 51.38% from -$1.2 million recorded in Q3 2019.
  • Over the past 5 years, DiaMedica Therapeutics' Cash from Operations peaked at -$935,000 during Q1 2018, and registered a low of -$3.1 million during Q1 2019.
  • In the last 2 years, DiaMedica Therapeutics' Cash from Operations had a median value of -$1.9 million in 2018 and averaged -$1.8 million.
  • Over the last 5 years, DiaMedica Therapeutics' Cash from Operations had its largest YoY gain of 32.97% in 2019, and its largest YoY loss of 235.19% in 2019.
  • DiaMedica Therapeutics' Cash from Operations (Quarterly) stood at -$1.9 million in 2018, then grew by 1.84% to -$1.9 million in 2019.
  • Its Cash from Operations stands at -$1.9 million for Q4 2019, versus -$1.2 million for Q3 2019 and -$2.9 million for Q2 2019.